This study assesses whether anti–factor Xa–guided dosing, compared with standard dosing, reduces the rate of venous thromboembolism in adults admitted to a level I trauma intensive care unit.
Key Points
Question
Is anti–factor Xa–guided dosing of enoxaparin sodium associated with the rate of venous thromboembolism after trauma?
Findings
In this review of 792 consecutive trauma patients, anti–factor Xa–guided dosing of enoxaparin was no better than a standard fixed dose of enoxaparin in preventing venous thromboembolism. Furthermore, anti–factor Xa levels in the prophylactic range did not prevent venous thromboembolism.
Meaning
If targeting the coagulation cascade does not optimize thromboprophylaxis, other targets, such as platelets, may be necessary.
Abstract
Importance
The efficacy of anti–factor Xa (anti-Xa)–guided dosing of thromboprophylaxis after trauma remains controversial.
Objective
To assess whether dosing of enoxaparin sodium based on peak anti-Xa levels is associated with the venous thromboembolism (VTE) rate after trauma.
Design, Setting, and Participants
Retrospective review of 950 consecutive adults admitted to a single level I trauma intensive care unit for more than 48 hours from December 1, 2014, through March 31, 2017. Within 24 hours of admission, these trauma patients were screened with the Greenfield Risk Assessment Profile (RAP) (possible score range, 0-46). Patients younger than 18 years and those with VTE on admission were excluded, resulting in a study population of 792 patients.
Exposures
The control group received fixed doses of either heparin sodium, 5000 U 3 times a day, or enoxaparin sodium, 30 mg twice a day. The adjustment cohort initially received enoxaparin sodium, 30 mg twice a day. A peak anti-Xa level was drawn 4 hours after the third dose. If the anti-Xa level was 0.2 IU/mL or higher, no adjustment was made. If the anti-Xa level was less than 0.2 IU/mL, each dose was increased by 10 mg. The process was repeated up to a maximum dose of 60 mg twice a day.
Main Outcomes and Measures
Rates of VTE were measured. Venous duplex ultrasonography and computed tomographic angiography were used for diagnosis.
Results
The study population comprised 792 patients with a mean (SD) age of 46 (19) years and was composed of 598 men (75.5%). The control group comprised 570 patients, was older, and had a longer time to thromboprophylaxis initiation. The adjustment group consisted of 222 patients, was more severely injured, and had a longer hospital length of stay. The mean (SD) RAP scores were 9 (4) for the control group and 9 (5) for the adjustment group (P = .28). The VTE rates were similar for both groups (34 patients [6.0%] vs 15 [6.8%]; P = .68). Prophylactic anti-Xa levels were reached in 119 patients (53.6%) in the adjustment group. No difference in VTE rates was observed between those who became prophylactic and those who did not (7 patients [5.9%] vs 8 [7.8%]; P = .58). To control for confounders, 132 patients receiving standard fixed-dose enoxaparin were propensity matched to 84 patients receiving dose-adjusted enoxaparin. The VTE rates remained similar between the control and adjustment groups (3 patients [2.3%] vs 3 [3.6%]; P = .57).
Conclusions and Relevance
Rates of VTE were not reduced with anti-Xa–guided dosing, and almost half of the patients never reached prophylactic anti-Xa levels; achieving those levels did not decrease VTE rates. Thus, other targets, such as platelets, may be necessary to optimize thromboprophylaxis after trauma.
Introduction
In 2008, the US Surgeon General declared venous thromboembolism (VTE) a major public health concern, leading to a call to action for VTE prevention. Furthermore, many national agencies, including the Centers for Medicare and Medicaid Services, have placed VTE in the category of “reasonably preventable” hospital-acquired conditions. In 2012, Thorson et al showed that, in high-risk trauma patients with a Risk Assessment Profile (RAP) score of 10 or higher, routine screening venous duplex ultrasonography identified a VTE rate of 28%, even with standard thromboprophylaxis (TPX). Most trauma centers have adopted a standard fixed-dose low-molecular-weight (LMW) heparin sodium as TPX, rather than unfractionated (UF) heparin. Despite this TPX regimen, the VTE rate continues to be high in the trauma population.
Current evidence suggests that anti–factor Xa (anti-Xa)–guided dosing of LMW heparin reduces the rate of VTE after trauma compared with the standard fixed dose of enoxaparin sodium. This evidence is based on 2 retrospective studies but includes several assumptions that could influence the interpretation of the results, such as small sample sizes, historical rather than contemporary controls, nonstandard TPX in control groups, unmatched groups, and no measurement of delayed TPX (Table 1).
Table 1. Comparison Between Present and Previous Study Designs .
| Variable | Singer et al,6 2016 | Ko et al,5 2016 | Present Study |
|---|---|---|---|
| Total patients, No. | 139 | 205 | 792 |
| Length of study, mo | 12 | 9 | 27 |
| Control source | Historical | Historical | Concurrent |
| Control TPX | UF heparin sodium, 5000 U 3 times a day | LMW heparin sodium, 30 mg twice a day | LMW heparin sodium, 30 mg twice a day |
| Randomized or matched? | No | No | Matched |
| Risk assessmenta | RAP score (at discharge) | None | RAP score (first 24 h) |
| Compares delayed TPX | No | No | Yes |
| Improved VTE rate | Yes | Yes | No |
Abbreviations: LMW, low-molecular-weight; RAP, Risk Assessment Profile; TPX, thromboprophylaxis; UF, unfractionated; VTE, venous thromboembolism.
The RAP score ranges from 0 to 46, with higher scores indicating higher risk.
In this study, we reexamined this idea and attempted to control for the multiple confounding variables. We tested the hypothesis that anti-Xa–guided dosing of enoxaparin rather than standard fixed dosing reduces the VTE rate after trauma. To our knowledge, this study is the largest to date on this topic.
Methods
This was a retrospective study conducted at the Ryder Trauma Center in the University of Miami/Jackson Memorial Medical Center, Miami, Florida. Adult patients with blunt or penetrating trauma admitted to the trauma intensive care unit (ICU) from December 1, 2014, through March 31, 2017, were prospectively screened for risk and included if they received chemical TPX. In addition to chemical TPX, mechanical TPX was used on the lower extremities of all patients with sequential compression devices unless injury prevented their use. Patients who were younger than 18 years, incarcerated, or pregnant; who died or had an ICU stay of less than 48 hours; or who had VTE on admission were excluded. This study was approved by the University of Miami/Jackson Memorial Medical Center Institutional Review Board; the need for patient consent was waived because this was a retrospective review that met all the standards for waiver of consent.
Risk for VTE was assessed with the RAP within the first 24 hours of admission to the ICU. The RAP score can range from 0 to 46. Per the ICU protocol, if the RAP score was 8 or higher, the patient was considered to be at high risk and received admission and weekly venous duplex ultrasonography of both lower extremities (inguinal ligament to ankle). Those with a RAP score less than 8 received venous duplex ultrasonography for symptomatic suspicion only. All pulmonary embolisms were diagnosed by computed tomographic angiography of the chest on symptomatic suspicion.
All patients initially received either standard-dose enoxaparin sodium, 30 mg administered subcutaneously twice a day, or standard-dose UF heparin sodium, 5000 U 3 times a day. In the adjustment group, a blood sample was drawn 4 hours after the third dose and the anti-Xa level was determined in the hospital pathology laboratory. According to previous studies, the target peak level considered to be prophylactic was 0.2 to 0.4 IU/mL. If the level was within this range, the enoxaparin sodium dose remained at 30 mg twice a day. If the level was subprophylactic, each enoxaparin sodium dose was increased by 10 mg. Another peak level was drawn after the third adjusted dose. If the level was still subprophylactic, enoxaparin doses were each increased by another 10 mg to a maximum of 60 mg twice a day. Patients with no TPX adjustment made up the control cohort.
Patients receiving the standard fixed-dose TPX including both enoxaparin and UF heparin were first compared with those receiving anti-Xa dose-adjusted enoxaparin. Propensity score matching was then used to reduce the confounding factors between those receiving the standard fixed-dose enoxaparin and those receiving dose-adjusted enoxaparin. An approximately 2:1 (control to adjustment) match was made to ensure the groups had the best match with the greatest sample size. Finally, a subgroup analysis was done within the dose-adjustment cohort to compare those with prophylactic anti-Xa levels (0.2-0.4 IU/mL) against those with subprophylactic anti-Xa levels (<0.2 IU/mL).
Statistical Analysis
All statistical analyses were performed using SPSS Statistics, version 22.0 (IBM Corporation). Categorical variables were expressed as frequency (percent) and compared between groups using χ2 or Fisher exact test, as appropriate. Parametric data are expressed as mean (SD) and compared using the unpaired, 1-tailed t test for 2 independent samples. Nonparametric data are expressed as median (interquartile range [IQR]) and compared using the Mann-Whitney test. All results were considered statistically significant at 1-sided P ≤ .05.
Results
A total of 950 trauma patients were admitted to the ICU within the study period. After exclusions, the study population comprised 792 patients with the following characteristics: mean (SD) age of 46 (19) years, composed of 598 men (75.5%), mean (SD) RAP score of 9 (4), mean (SD) Injury Severity Score of 20 (12), and median hospital length of stay (LOS) of 15 (IQR, 8-31) days. The overall VTE rate was 6.2% (n = 49), with 4.3% (n = 34) deep venous thrombosis and 2.4% (n = 19) pulmonary embolism. All deep venous thromboses were in the lower extremities, above the knee. Standard fixed-dose TPX was given to 570 patients (control group), and 222 patients (adjustment group) received anti-Xa–guided dosing of enoxaparin. Table 2 shows multiple differences in VTE risk factors, but the overall rates of thrombotic complications—including deep venous thrombosis, and pulmonary embolism—were no different between the control and adjustment groups.
Table 2. Comparison Between Control and Adjustment Groups.
| Variable | Control Group (n = 570) |
Adjustment Group (n = 222) |
P Value |
|---|---|---|---|
| Age, mean (SD), y | 48 (20) | 40 (16) | <.001a |
| Male, No. (%) | 423 (74.2) | 175 (78.8) | .16 |
| LOS, median (IQR), d | 13 (7-25) | 21 (11-41) | <.001a |
| ISS score, mean (SD)b | 20 (11) | 22 (13) | .04a |
| RAP score, mean (SD)c | 9 (4) | 9 (5) | .28 |
| Obesity (BMI ≥30), No. (%) | 82 (14.4) | 62 (27.9) | <.001a |
| History of VTE, No. (%) | 10 (1.8) | 4 (1.8) | .96 |
| Malignant neoplasm, No. (%) | 35 (6.1) | 12 (5.4) | .69 |
| Abnormal coagulation laboratory results, No. (%) | 150 (26.3) | 83 (37.4) | .002a |
| Femoral venous line, No. (%) | 32 (5.6) | 29 (13.1) | <.001a |
| Pelvic fracture, No. (%) | 143 (25.1) | 53 (23.9) | .72 |
| Spinal cord injury, No. (%) | 105 (18.4) | 23 (10.4) | .006a |
| ≥4 Transfusions, No. (%) | 115 (20.2) | 66 (29.7) | .004a |
| Operation time ≥2 h, No. (%) | 104 (18.2) | 60 (27.0) | .006a |
| Venous repair or ligation, No. (%) | 56 (9.8) | 24 (10.8) | .68 |
| AIS score, No. (%)d | |||
| Head >2 | 249 (43.7) | 36 (16.2) | <.001a |
| Chest >2 | 208 (36.5) | 97 (43.7) | .06 |
| Abdomen >2 | 170 (29.8) | 89 (40.1) | .006a |
| GCS score <8, No. (%)e | 111 (19.5) | 20 (9.0) | <.001a |
| Lower extremity fracture, No. (%) | 89 (15.6) | 35 (15.8) | .96 |
| Initiation of prophylaxis, median (IQR), d | 1 (0-3) | 0 (0-2) | <.001a |
| Delayed (>48 h) prophylaxis, No. (%) | 236 (41.5) | 47 (21.3) | <.001a |
| Venous thromboembolism, No. (%) | 34 (6.0) | 15 (6.8) | .68 |
| Deep venous thrombosis, No. (%) | 23 (4.0) | 11 (5.0) | .57 |
| Pulmonary embolism, No. (%) | 14 (2.5) | 5 (2.3) | .87 |
Abbreviations: AIS, Abbreviated Injury Scale; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GCS, Glasgow Coma Scale; IQR, interquartile range; ISS, Injury Severity Score; LOS, length of stay; RAP, Risk Assessment Profile.
Statistically significant.
The ISS ranges from 0 to 75, with the highest score indicating an unsurvivable injury.
The RAP score ranges from 0 to 46, with higher scores indicating higher risk.
The AIS score ranges from 1 to 6, with the highest score being currently untreatable.
The GCS score ranges from 3 to 15, with the highest score indicating awake, alert, and following commands.
To reduce confounding VTE risk factors, the control group (receiving standard fixed-dose enoxaparin) and the adjustment group (receiving dose-adjusted enoxaparin) were propensity matched. One hundred thirty-two patients receiving enoxaparin sodium, 30 mg twice a day, were matched to 84 patients receiving dose-adjusted enoxaparin based on age, Injury Severity Score, RAP score, LOS, and time to initiation of TPX. Only 2 differences were found after matching (Table 3). The rates of thrombotic complications remained similar between the control and adjustment groups.
Table 3. Propensity Score Matching: Standard Fixed-Dose and Dose-Adjusted Enoxaparin.
| Variablea | Standard Fixed-Dose Enoxaparin Sodium (n = 132) |
Dose-Adjusted Enoxaparin (n = 84) |
P Value |
|---|---|---|---|
| Age, mean (SD), y | 43 (19) | 42 (17) | .68 |
| Male, No. (%) | 96 (72.7) | 67 (79.8) | .24 |
| LOS, median (IQR), d | 12 (6-21) | 13 (8-26) | .09 |
| ISS score, mean (SD) | 18 (11) | 18 (10) | .71 |
| RAP score, mean (SD) | 8 (4) | 7 (4) | .71 |
| Obesity (BMI ≥30), No. (%) | 23 (17.4) | 22 (26.2) | .12 |
| History of VTE, No. (%) | 3 (2.3) | 2 (2.4) | .96 |
| Malignant neoplasm, No. (%) | 3 (2.3) | 0 (0.0) | .16 |
| Abnormal coagulation laboratory results, No. (%) | 36 (27.3) | 23 (27.4) | .99 |
| Femoral venous line, No. (%) | 7 (5.3) | 9 (10.7) | .14 |
| Pelvic fracture, No. (%) | 23 (17.4) | 11 (13.1) | .39 |
| Spinal cord injury, No. (%) | 21 (15.9) | 3 (3.6) | .005b |
| ≥4 Transfusions, No. (%) | 17 (12.9) | 22 (26.2) | .01b |
| Operation time ≥2 h, No. (%) | 30 (22.7) | 22 (26.2) | .53 |
| Venous repair or ligation, No. (%) | 13 (9.8) | 5 (6.0) | .31 |
| AIS score, No. (%) | |||
| Head >2 | 36 (27.3) | 16 (19.0) | .17 |
| Chest >2 | 63 (47.7) | 39 (46.4) | .85 |
| Abdomen >2 | 43 (32.6) | 31 (36.9) | .51 |
| GCS score <8, No. (%) | 11 (8.3) | 4 (4.8) | .31 |
| Lower extremity fracture, No. (%) | 15 (11.4) | 9 (10.7) | .88 |
| Initiation of prophylaxis, median (IQR), d | 0 (0-1) | 0 (0-1) | .13 |
| Delayed (>48 h) prophylaxis, No. (%) | 25 (18.9) | 13 (15.5) | .59 |
| VTE, No. (%) | 3 (2.3) | 3 (3.6) | .57 |
| Deep venous thrombosis, No. (%) | 2 (1.5) | 1 (1.2) | .84 |
| Pulmonary embolism, No. (%) | 2 (1.5) | 2 (2.4) | .65 |
Abbreviations: AIS, Abbreviated Injury Scale; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GCS, Glasgow Coma Scale; IQR, interquartile range; ISS, Injury Severity Score; LOS, length of stay; RAP, Risk Assessment Profile; VTE, venous thromboembolism.
The ISS, RAP, AIS, and GCS scores are explained in footnotes to Table 2.
Statistically significant.
Within the adjustment cohort, only 119 (53.6%) reached anti-Xa levels of 0.2 to 0.4 IU/mL at any point during their hospital LOS. Comparing these patients with those who never reached prophylactic levels, we found no factor associated with the inability to reach a prophylactic level. Furthermore, thrombotic complication rates between the groups were not different (Table 4).
Table 4. Subprophylactic and Prophylactic Anti-Xa Levels During Hospital Stay.
| Variablea | Subprophylactic Level (n = 103) |
Prophylactic Level (n = 119) |
P Value |
|---|---|---|---|
| Age, mean (SD), y | 40 (15) | 40 (17) | .89 |
| Male, No. (%) | 80 (77.7) | 95 (79.8) | .69 |
| ISS score, mean (SD) | 22 (14) | 21 (13) | .64 |
| RAP score, mean (SD) | 9 (4) | 8 (5) | .57 |
| Obesity (BMI ≥30), No. (%) | 29 (28.2) | 33 (27.7) | .94 |
| History of VTE, No. (%) | 3 (2.9) | 1 (0.8) | .25 |
| Malignant neoplasm, No. (%) | 8 (7.8) | 4 (3.4) | .15 |
| Abnormal coagulation laboratory results, No. (%) | 40 (38.8) | 43 (36.1) | .68 |
| Femoral venous line, No. (%) | 15 (14.6) | 14 (11.8) | .54 |
| Pelvic fracture, No. (%) | 28 (27.2) | 25 (21.0) | .28 |
| Spinal cord injury, No. (%) | 15 (14.6) | 8 (6.7) | .06 |
| ≥4 Transfusions, No. (%) | 29 (28.2) | 37 (31.1) | .63 |
| Operation time ≥2 h, No. (%) | 29 (28.2) | 31 (26.1) | .73 |
| Venous repair or ligation, No. (%) | 15 (14.6) | 9 (7.6) | .09 |
| AIS score, No. (%) | |||
| Head >2 | 15 (14.6) | 21 (17.6) | .53 |
| Chest >2 | 39 (38.9) | 58 (48.7) | .10 |
| Abdomen >2 | 41 (39.8) | 48 (40.3) | .94 |
| GCS score <8, No. (%) | 7 (6.8) | 13 (11.0) | .28 |
| Lower extremity fracture, No. (%) | 16 (15.5) | 19 (16.0) | .93 |
| Initiation of prophylaxis, median (IQR), d | 0 (0-2) | 0 (0-2) | .99 |
| Delayed (>48 h) prophylaxis, No. (%) | 22 (21.4) | 25 (21.2) | .98 |
| VTE, No. (%) | 8 (7.8) | 7 (5.9) | .58 |
| Deep venous thrombosis, No. (%) | 7 (6.8) | 4 (3.4) | .24 |
| Pulmonary embolism, No. (%) | 1 (1.0) | 4 (3.4) | .23 |
Abbreviations: AIS, Abbreviated Injury Scale; anti-Xa, anti–factor Xa; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GCS, Glasgow Coma Scale; IQR, interquartile range; ISS, Injury Severity Score; RAP, Risk Assessment Profile; VTE, venous thromboembolism.
The ISS, RAP, AIS, and GCS scores are explained in footnotes to Table 2.
Discussion
To our knowledge, this is the largest trauma study population to date, and the major findings are as follows: (1) VTE rates were similar with anti-Xa–guided dosing or standard fixed-dose TPX after trauma; (2) almost half the patients never achieved an anti-Xa level of 0.2 IU/mL or higher during their hospital LOS despite progressively increasing doses of enoxaparin; and (3) VTE rates were similar regardless of the anti-Xa level. This third finding supports the interpretation that, at least in trauma patients with moderate to high risk for VTE, anti-Xa levels may not be as useful as previously suspected for titrating TPX. Furthermore, given that increasing doses of enoxaparin did not reduce VTE rates, other targets, such as platelets, may be necessary to optimize TPX.
Rates of VTE after trauma remain high despite multiple strategies for optimizing TPX. Current guidelines recommend LMW heparin for TPX, but VTE rates can still range from 3% to 44% depending on risk factors. To address refractory VTE, at least 3 strategies can be used for dosing LMW heparin: thromboelastography weight-based or anti-Xa–based methods. Each has its proponents and has shown promise in specific conditions, but there is still no consensus on which strategy is best.
Several studies have focused on the use of anti-Xa level for TPX. Several studies have focused on anti-Xa to optimize TPX. Because LMW heparin binds to antithrombin III (ATIII), it initiates a conformational change and ultimately leads to the acceleration of factor Xa inhibition. Although ATIII is the major molecule that interacts with LMW heparin to affect the coagulation cascade, many downstream coagulation factors are also inactivated through this mechanism. Measurement of anti-Xa involves a chromogenic response from the cleavage of a tagged substrate by unbound factor Xa. This result reflects the level of anticoagulation and can thus be used to guide TPX.
Singer et al performed one of the first studies to investigate anti-Xa–guided dosing of enoxaparin. Those researchers initiated a dose adjustment protocol on the basis of peak anti-Xa levels over a 12-month period. Comparing their results with those of a historical cohort, Singer et al concluded that the deep venous thrombosis rate was significantly reduced with the dosing protocol. Ko et al reached a similar conclusion; the VTE rate was reduced compared with the rate of a historical cohort.
One problem with the study by Singer et al is the comparison with a historical cohort receiving UF heparin. In 1996, a randomized clinical trial found that LMW heparin prevented more VTEs than did UF heparin after trauma, effectively making LMW heparin the recommended TPX. Many studies since, including 2 large multicenter analyses, have similarly found that LMW heparin is superior to UF heparin for preventing VTE after trauma. Inherently, these findings undermine the comparison of dosing regimens with a less effective control group receiving UF heparin.
Table 1 highlights another issue addressed with our analysis—delayed TPX initiation. Both delayed initiation and missed doses of TPX have been associated with higher VTE rates after trauma. This risk factor is frequently overlooked. We attempted in our analysis to ameliorate the impact of delayed prophylaxis by using propensity score matching; previous studies did not consider this variable.
First, we compared the dose-adjustment cohort with standard TPX of either enoxaparin sodium, 30 mg twice a day, or UF heparin sodium, 5000 U 3 times a day. Although this comparison has the same inherent bias as that stated in previous studies, it allowed for any baseline differences between the groups to emerge. There were several risk factor differences between the cohorts that could affect the thrombotic complication rates of either group (Table 2). Second, we isolated all the patients receiving only enoxaparin and matched the groups according to differences in age, Injury Severity Score, RAP score, time to initiation of TPX, and LOS (Table 3). This approach allowed a comparison of anti-Xa–guided dosing with the accepted standard-dose TPX (enoxaparin sodium, 30 mg twice a day) among appropriately matched cohorts.
We recognize that absence of proof is not proof of absence; thus, our failure to find a VTE difference with anti-Xa–guided enoxaparin dosing does not necessarily mean that a dose less than 60 mg twice a day would not reduce the VTE rates. The risk of bleeding must be balanced with the risk of VTE. Our main goal, however, was to evaluate the process of using a peak anti-Xa level as a surrogate for adequate prophylaxis. Perhaps failure to reduce the VTE incidence may be associated with failure to reach the anti-Xa prophylactic range of 0.2 to 0.4 IU/mL. In fact, only 53.6% of our patients reached this range, which is consistent with other reports. By comparing the group achieving a prophylactic range with the group remaining at a subprophylactic level, we derived 2 conclusions. First, no variable evaluated was associated with the inability to reach the prophylactic anti-Xa level. Second, reaching a prophylactic anti-Xa level did not reduce the VTE rate, indicating that the range may not truly be prophylactic (Table 4).
One likely explanation why reaching a prophylactic level of anti-Xa may not be sufficient is related to an ATIII deficiency after trauma. Both UF heparin and LMW heparin, bind to ATIII, forming a complex that leads to the deactivation of clotting factors—mainly, factor Xa. This typically seen deficiency would logically decrease the impact of the heparin-based anticoagulation, thus producing a higher VTE rate.
Furthermore, in the past 2 decades, optimizing TPX in the trauma population has focused on controlling the coagulation cascade. Despite various TPX strategies, refractory VTE persists. Evidence from this study suggests that we may be exhausting our efforts to alter the consequences of coagulation factors. Evolving evidence shows that new targets, including platelets and fibrinolysis, may be the next step toward optimal TPX. Both heparin and LMW heparin induce platelet aggregation. Furthermore, heparinoids interact with the platelet surface, changing platelet morphology, and promote the expression of P-selectin. By activating platelets in this way, crosslinking of fibrinogen to αIIbβ3 is upregulated, ultimately supporting platelet aggregation. This basic mechanism has been confirmed in the clinical setting by Harr et al, who showed that thromboelastography-guided increases in heparin dose amplified platelet contribution to clot strength. Harr et al also noticed a 2-fold increase in LMW heparin had no influence on thromboelastography reaction time, showing that hypercoagulability may be resistant to standard heparin-based TPX. Connelly et al showed similar results with thromboelastography reaction times. These results suggest a possible explanation for why VTE is not eliminated with increasing doses of LMW heparin and why other factors, such as platelets, may participate.
Limitations
The results and interpretations of the present study must be considered in the context of its limitations. This study was a retrospective review and thus was not randomized. We attempted to address this issue by propensity score matching, but even though the patients were ultimately well matched, matching introduces a selection bias into the study. The ideal evaluation would include prospective, randomized cohorts, but in the absence of such, propensity score matching allows for the comparison of similar groups to avoid the inherent bias of nonrandomized, unmatched cohorts. Furthermore, because negative results were the main finding, we can only conclude that there was a failure to find a reduction in VTE rate. Despite this failure, we have conducted the largest and longest study to date (to our knowledge) that evaluated patients who were adequately matched regarding anti-Xa dosing of TPX.
Conclusions
Venous thromboembolism rates did not decrease over a 27-month period with anti-Xa–guided dosing of enoxaparin. Furthermore, about half of the trauma patients in the study were unable to reach a prophylactic anti-Xa level during their hospital stay despite repeated increases in dosing. Even the patients who achieved prophylactic anti-Xa levels did not see a reduced VTE rate. Based on these results, we are skeptical of the clinical use of anti-Xa to guide TPX after trauma, especially considering increased surveillance, time, and cost for testing and higher doses of medication. At this point, we believe that we may not be able to optimize TPX by targeting only the coagulation factors. Our results, along with other emerging evidence, suggest that other additional targets—such as platelets—could hold great promise for decreasing VTE after trauma.
References
- 1.Office of the Surgeon General; National Heart, Lung, and Blood Institute . The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism: Publications and Reports of the Surgeon General. Rockville, MD: US Office of the Surgeon General; 2008. [PubMed] [Google Scholar]
- 2.Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev. 2013;(3):CD008303. [DOI] [PubMed] [Google Scholar]
- 3.Centers for Medicare & Medicaid Services Hospital-acquired conditions. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired_Conditions.html. Modified August 19, 2015. Accessed May 16, 2017.
- 4.Thorson CM, Ryan ML, Van Haren RM, et al. Venous thromboembolism after trauma: a never event?* Crit Care Med. 2012;40(11):2967-2973. [DOI] [PubMed] [Google Scholar]
- 5.Ko A, Harada MY, Barmparas G, et al. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg. 2016;151(11):1006-1013. [DOI] [PubMed] [Google Scholar]
- 6.Singer GA, Riggi G, Karcutskie CA, et al. Anti-Xa–guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2016;81(6):1101-1108. [DOI] [PubMed] [Google Scholar]
- 7.Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med. 1995;15(1):119-123. [PubMed] [Google Scholar]
- 8.Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064-1083. [DOI] [PubMed] [Google Scholar]
- 9.Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010;29(2):233-240. [DOI] [PubMed] [Google Scholar]
- 10.Harr JN, Moore EE, Chin TL, et al. Platelets are dominant contributors to hypercoagulability after injury. J Trauma Acute Care Surg. 2013;74(3):756-762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Brill JB, Calvo RY, Wallace JD, et al. Aspirin as added prophylaxis for deep vein thrombosis in trauma: a retrospective case-control study. J Trauma Acute Care Surg. 2016;80(4):625-630. [DOI] [PubMed] [Google Scholar]
- 12.Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331(24):1601-1606. [DOI] [PubMed] [Google Scholar]
- 13.Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel . Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):7S-47S. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(10):701-707. [DOI] [PubMed] [Google Scholar]
- 15.Pierce CA, Haut ER, Kardooni S, et al. Surveillance bias and deep vein thrombosis in the National Trauma Data Bank: the more we look, the more we find. J Trauma. 2008;64(4):932-936. [DOI] [PubMed] [Google Scholar]
- 16.Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma. 1992;32(1):2-11. [DOI] [PubMed] [Google Scholar]
- 17.Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. J Trauma. 1994;37(3):480-487. [DOI] [PubMed] [Google Scholar]
- 18.Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma. 1996;41(3):446-459. [DOI] [PubMed] [Google Scholar]
- 19.Connelly CR, Van PY, Hart KD, et al. Thrombelastography-based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: a randomized clinical trial. JAMA Surg. 2016;151(10):e162069. [DOI] [PubMed] [Google Scholar]
- 20.Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg. 2013;206(6):847-851. [DOI] [PubMed] [Google Scholar]
- 21.Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003;90(5):547-548. [DOI] [PubMed] [Google Scholar]
- 22.Costantini TW, Min E, Box K, et al. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg. 2013;74(1):128-133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kopelman TR, O’Neill PJ, Pieri PG, et al. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? Am J Surg. 2013;206(6):911-915. [DOI] [PubMed] [Google Scholar]
- 24.Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma. 2010;68(4):874-880. [DOI] [PubMed] [Google Scholar]
- 25.Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21(2):218-234. [DOI] [PubMed] [Google Scholar]
- 26.Byrne JP, Geerts W, Mason SA, et al. Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: a propensity-matched analysis. J Trauma Acute Care Surg. 2017;82(2):252-262. [DOI] [PubMed] [Google Scholar]
- 27.Jacobs BN, Cain-Nielsen AH, Jakubus JL, et al. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg. 2017;83(1):151-158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Louis SG, Sato M, Geraci T, et al. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg. 2014;149(4):365-370. [DOI] [PubMed] [Google Scholar]
- 29.Nathens AB, McMurray MK, Cuschieri J, et al. The practice of venous thromboembolism prophylaxis in the major trauma patient. J Trauma. 2007;62(3):557-562. [DOI] [PubMed] [Google Scholar]
- 30.Louis SG, Van PY, Riha GM, et al. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. J Trauma Acute Care Surg. 2014;76(4):937-942. [DOI] [PubMed] [Google Scholar]
- 31.Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97(3):251-256. [DOI] [PubMed] [Google Scholar]
- 32.Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res. 1988;50(6):815-826. [DOI] [PubMed] [Google Scholar]
- 33.Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol. 2007;100(3):417-424. [DOI] [PubMed] [Google Scholar]
- 34.Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33(3):587-594. [DOI] [PubMed] [Google Scholar]
- 35.Yagi M, Murray J, Strand K, et al. Heparin modulates the conformation and signaling of platelet integrin αIIbβ3. Thromb Res. 2012;129(6):743-749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood. 2011;117(18):4946-4952. [DOI] [PMC free article] [PubMed] [Google Scholar]